ReviewCurrent medicinal chemistry2008
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.
Review in Current medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 124 citations in OpenAlex.
- Rosuvastatin for sepsis-associated acute respiratory distress syndrome.The New England journal of medicine · 2014Trial
- Article
- Hyaluronic acid-based microgels loaded with fluticasone furoate for bleomycin-induced acute lung injury treatment.Materials today. Bio · 2025Article
- Long Noncoding RNA: A Novel Insight into the Pathogenesis of Acute Lung Injury.Journal of clinical medicine · 2023Review
- Article
- Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives.Stem cell reviews and reports · 2021Review
- Acute Respiratory Distress Syndrome and COVID-19: A Literature Review.Journal of inflammation research · 2021Review
- A Competitive Endogenous RNA Network Based on Differentially Expressed lncRNA in Lipopolysaccharide-Induced Acute Lung Injury in Mice.Frontiers in genetics · 2021Article
- A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.Experimental cell research · 2020Article
- Deficiency of cationic amino acid transporter-2 protects mice from hyperoxia-induced lung injury.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Targeting F-Box Protein Fbxo3 Attenuates Lung Injury Induced by Ischemia-Reperfusion in Rats.Frontiers in pharmacology · 2019Article
- Role of Quzhou Fructus Aurantii Extract in Preventing and Treating Acute Lung Injury and Inflammation.Scientific reports · 2018Article
- Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Review
- Article
- The Src family tyrosine kinases src and yes have differential effects on inflammation-induced apoptosis in human pulmonary microvascular endothelial cells.American journal of physiology. Lung cellular and molecular physiology · 2016Article
- Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-κB Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic Function.International journal of molecular sciences · 2016Article
- Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.Frontiers in pediatrics · 2016Review
- Observational
- The impact of pretreatment with bolus dose of enteral glutamine on acute lung injury induced by oleic acid in rats.Journal of anesthesia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to single-agent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.